Video
5m Watch
April 30, 2025
COMMUNITY AND GLOBAL HEALTH
The Need
- Each day, more than 3,400 people lose their lives to TB and nearly 30,000 people fall ill with this preventable and curable disease1
- IIn the United States, there were 10,347 cases reported, an 8% increase from 2023. 2
- Precise and early detection of TB is needed to improve case management and significantly enhance the prevention of TB transmission2
1 Global Tuberculosis Report 2023. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023. Accessed Jan 2024.
2 The Global Statistics. Tuberculosis Facts in the U.S. 2025| TB Stats. Accessed March 2026. https://www.theglobalstatistics.com/united-states-tuberculosis-facts
2 The Global Statistics. Tuberculosis Facts in the U.S. 2025| TB Stats. Accessed March 2026. https://www.theglobalstatistics.com/united-states-tuberculosis-facts
The Solution
The Xpert MTB/RIF test provides fast and accurate detection of Mycobacterium Tuberculosis (MTB) and Rifampicin (RIF) resistance simultaneously from patient samples
- Simple three-step process with results in less than 2 hours
- Designed to provide the most accurate MTB and Rifampicin detection
- On‑demand testing supports clinician decision‑making
The Impact
- Supports timely clinical decision‑making by providing rapid detection of MTB and RIF resistance4
- May be used as an aid to decisions regarding continued AII (airborne infection isolation), potentially reducing AII duration versus serial smear in certain settings4
- Economic modeling studies in US settings have found implementation is cost‑effective for diagnosing pulmonary TB in the United States5
3 Centers for Disease Control and Prevention—Guidelines for preventing the transmission of TB-- https://www.cdc.gov/mmwr/preview/mmwrhtml/00001897.htm. Accessed Jan 2024.
4 Christopher K. Lippincott et al, Xpert MTB/RIF Assay Shortens Airborne Isolation for Hospitalized Patients With Presumptive Tuberculosis in the United States Clin Infect Dis. 2014 Jul 15; 59(2): 186–19
5 H. W. Choi, et al, Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States Int J Tuberc Lung Dis. 2013 October ; 17(10): 1328–1335
4 Christopher K. Lippincott et al, Xpert MTB/RIF Assay Shortens Airborne Isolation for Hospitalized Patients With Presumptive Tuberculosis in the United States Clin Infect Dis. 2014 Jul 15; 59(2): 186–19
5 H. W. Choi, et al, Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States Int J Tuberc Lung Dis. 2013 October ; 17(10): 1328–1335